alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
§ 876.5210 Enema kit. ( a ) *Identification.* An enema kit is a device intended to instill water or other fluids into the colon through a nozzle inserted into the rectum to promote evacuation of the contents of the lower colon. The device consists of a container for fluid connected to the nozzle either directly or via tubing. This device does not include the colonic irrigation system (§ 876.5220).
( b ) *Classification.* Class I (general controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to § 876.9. The device is exempt from the current good manufacturing practice requirements of the quality system regulation in part 820 of this chapter, with the exception of § 820.180 of this chapter, with respect to general requirements concerning records, and § 820.198 of this chapter, with respect to complaint files.
[48 FR 53023, Nov. 23, 1963, as amended at 65 FR 2317, Jan. 14, 2000]
| (logo) WELLS FARGO | **Commercial Mortgage Servicing**D1050-084, 8th Fl  401 South Tryon Street  Charlotte, NC 28202  1-800-326-1334 |
|--------------------|-----------------------------------------------------------------------------------------------------------------|

 

ANNUAL STATEMENT OF COMPLIANCE

 

Reference is hereby made tothat certain Pooling and Servicing Agreement  dated as  of June 1,2015, by and among Morgan Stanley Capital I Inc., as Depositor, Wells FargoBank, National Association, as Master Servicer, LNR Partners, LLC, as GeneralSpecial Servicer, Wells Fargo Bank, National Association, as Excluded MortgageLoan Special Servicer, Pentalpha Surveillance LLC, as Trust Advisor, WilmingtonTrust, National Association, as Trustee,  and  Wells Fargo Bank,National Association, as Certificate Administrator, Certificate Registrar,Authenticating Agent and Custodian with respect to Commercial MortgagePass-Through Certificates Series 2015-C23 (the "Agreement").Capitalized terms used herein not otherwise defined shall have the meaningsassigned in the Agreement.

 

Pursuant to Section 13.9 ofthe Agreement, I, Daniel Bober, Executive Vice President of Commercial MortgageServices do hereby certify that:

 

1.       A review of the activities of the Master Servicer during the period fromJanuary 1, 2016 through December 31, 2016 (the “Reporting Period”),and of its performance per the Agreement during such period has been made undermy supervision, and

 

2.       To the best of my knowledge, based on such review, the Master Servicer, hasfulfilled all of its obligations under the Agreement in all material respectsthroughout the Reporting Period.

 

 

IN WITNESS WHEREOF, theundersigned has executed this Certificate as of the 28th day of February 2017.

 

/s/ Daniel Bober

Daniel Bober

Executive Vice President

Wells Fargo Bank

 

 

| Wells Fargo Bank, N.A. | (logo) Together we’ll  go far |
|------------------------|-------------------------------------|
Editorial Note on Part 890
Editorial Note: Nomenclature changes to part 890 appear at 73 FR 35341, June 23, 2008.

§ 890.5760 Nonpowered lower extremity pressure wrap. ( a ) *Identification.* A nonpowered lower extremity pressure wrap is a prescription device that applies mechanical pressure by wrapping around the lower extremity, such as the leg or foot, and is intended for primary Restless Leg Syndrome.
( b ) *Classification.* Class I (general controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter, subject to the limitations in § 890.9.
[79 FR 37950, July 3, 2014]
* Pursuant to 5 T H C IR

. R. 47.5, the court has determined that

this opinion should not be published and is not precedent except

under the limited circumstances set forth in 5 TH C IR

. R. 47.5.4. United States Court of Appeals

Fifth Circuit



## FILED

September 3, 2003

Charles R. Fulbruge III

Clerk IN THE UNITED STATES COURT OF APPEALS

FOR THE FIFTH CIRCUIT

No. 03-30059

Summary Calendar

UNITED STATES OF AMERICA,

Plaintiff-Appellee,

versus

RENIFER JOHN MCFADDEN,

Defendant-Appellant.

Appeal from the United States District Court

for the Eastern District of Louisiana

USDC No. 02-CR-149-ALL

Before HIGGINBOTHAM, DAVIS, and PRADO, Circuit Judges.

PER CURIAM: *

Renifer John McFadden appeals from his sentence entered after

a guilty plea conviction for possession of a firearm by a felon in

violation of 18 U.S.C. §§ 922(g)(1) and 924(a)(2) and for making a

false statement as to a fact material to the lawfulness of the sale

of a firearm in violation of 18 U.S.C. §§ 922(a)(6) and

924(a)(1)(B). He argues that the district court erred in denying1 See United States v. Solis , 299 F.3d 420, 458 (5th Cir.

2002) (“While we generally review a district court’s factual

finding under the Guidelines for clear error, [a] district court’s

determination of whether a defendant is entitled to a reduction of

his offense level for acceptance of responsibility is reviewed with

even more deference than the pure clearly erroneous standard. As

such, [w]e will affirm a sentencing court’s decision not to award

a reduction under U.S.S.G. § 3E1.1 unless it is wi thout

foundation.” (footnote and internal quotation marks omitted)).

2 an offense level reduction for acceptance of responsibility under

U.S.S.G. § 3E1.1. However, the district court provided several

reasons supporting its doubt of McFadden’s true acceptance of

responsibility. 1 Giving great deference to the district court’s

decision to deny sentencing leniency under U.S.S.G. § 3 E1.1, we

AFFIRM.
<TABLE> <S> <C>

<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM THE RESTATED
CONSOLIDATED FINANCIAL STATEMENTS OF HARBINGER CORPORATION FOR THE YEAR ENDED
DECEMBER 31, 1997 AND IS QUALIFIED IN ITS ENTIRETY BY REFERENCE TO SUCH
CONSOLIDATED FINANCIAL STATEMENTS.
</LEGEND>
<RESTATED> 
<MULTIPLIER> 1000
       
<S>                             <C>
<PERIOD-TYPE>                   YEAR
<FISCAL-YEAR-END>                          DEC-31-1997
<PERIOD-START>                             JAN-01-1997
<PERIOD-END>                               DEC-31-1997
<CASH>                                          69,811
<SECURITIES>                                    32,333
<RECEIVABLES>                                   37,807
<ALLOWANCES>                                     2,790
<INVENTORY>                                          0
<CURRENT-ASSETS>                               147,848
<PP&E>                                          33,788
<DEPRECIATION>                                  15,621
<TOTAL-ASSETS>                                 183,559
<CURRENT-LIABILITIES>                           53,541
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                             4
<OTHER-SE>                                     130,014
<TOTAL-LIABILITY-AND-EQUITY>                   183,559
<SALES>                                         54,804
<TOTAL-REVENUES>                               118,221
<CGS>                                            7,800
<TOTAL-COSTS>                                   30,510
<OTHER-EXPENSES>                               110,416
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                 132
<INCOME-PRETAX>                                (19,102)
<INCOME-TAX>                                     3,093
<INCOME-CONTINUING>                            (22,195)
<DISCONTINUED>                                 (14,433)
<EXTRAORDINARY>                                 (2,419)
<CHANGES>                                            0
<NET-INCOME>                                   (39,047)
<EPS-PRIMARY>                                    (1.02)
<EPS-DILUTED>                                    (1.02)
        

</TABLE>
# C_2014339EN.01002001.xml

| 29.9.2014 | EN | Official Journal of the European Union | C 339/20 |
| --- | --- | --- | --- |

29.9.2014

EN

Official Journal of the European Union

C 339/20

---

Action brought on 16 July 2014 — Sheraton International IP v OHIM — Staywell Hospitality Group (PARK REGIS)

(Case T-536/14)

2014/C 339/24

Language in which the application was lodged: English

Parties

Parties

Applicant: Sheraton International IP LLC (Stamford, United States) (represented by: E. Armijo Chávarri, lawyer)

Applicant:

Defendant: Office for Harmonisation in the Internal Market (Trade Marks and Designs)

Defendant:

Other party to the proceedings before the Board of Appeal: Staywell Hospitality Group Pty Ltd (Sydney, Australia)

Other party to the proceedings before the Board of Appeal:

Form of order sought

Form of order sought

The applicant claims that the Court should:

| — | Annul the decision of the Fifth Board of Appeal of the Office for Harmonisation in the Internal Market (Trade Marks and Designs) of 30 April 2014 given in joined Cases R 240/2013-5 and R 303/2013-5; |
| --- | --- |

—

Annul the decision of the Fifth Board of Appeal of the Office for Harmonisation in the Internal Market (Trade Marks and Designs) of 30 April 2014 given in joined Cases R 240/2013-5 and R 303/2013-5;

| — | Order the defendant to pay the costs of proceedings. |
| --- | --- |

—

Order the defendant to pay the costs of proceedings.

Pleas in law and main arguments

Pleas in law and main arguments

Applicant for a Community trade mark: The other party to the proceedings before the Board of Appeal

Applicant for a Community trade mark:

Community trade mark concerned: The figurative mark containing the verbal elements ‘PARK REGIS’ for services in Classes 35, 36 and 43 — Community trade mark application No 9 4 88  933

Community trade mark concerned:

Proprietor of the mark or sign cited in the opposition proceedings: The applicant

Proprietor of the mark or sign cited in the opposition proceedings:

Mark or sign cited in opposition: CTM registrations, International trade mark registrations and well-known mark ‘ST REGIS’

Mark or sign cited in opposition:

Decision of the Opposition Division: Upheld the opposition in part

Decision of the Opposition Division:

Decision of the Board of Appeal: Dismissed the appeal

Decision of the Board of Appeal:

Pleas in law: Infringement of Article 8(1)(b) CTMR.

Pleas in law:

---
TEXAS COURT OF APPEALS, THIRD DISTRICT, AT AUSTIN

NO. 03-18-00053-CV

Glenn Hegar, Comptroller of Public Accounts of the State of Texas; and 

Ken Paxton, Attorney General of the State of Texas, Appellants

v.

Michael D’s Restaurant San Antonio, Inc., Appellee

FROM THE 250TH DISTRICT COURT OF TRAVIS COUNTY

NO. D-1-GN-17-005915, THE HONORABLE KARIN CRUMP, JUDGE PRESIDING

M E M O R A N D U M O P I N I O N 

The parties have filed an agreed motion to dismiss this appeal. The parties inform 

us that appellee has nonsuited its claims in the trial court. The parties move for dismissal of the 

appeal with prejudice to its refiling by any party. We grant the motion and dismiss the appeal. 

See Tex. R. App. P. 42.1(a)(2)(A).

__________________________________________

Jeff Rose, Chief Justice

Before Chief Justice Rose, Justices Baker and Kelly

Dismissed on Agreed Motion

Filed: October 2, 2020
Editorial Note on Part 73
Editorial Note: Nomenclature changes to part 73 appear at 66 FR 66742, Dec. 27, 2001.

§ 73.2645 Aluminum powder. ( a ) *Identity and specifications.* The color additive aluminum powder shall conform in identity and specifications to the requirements of § 73.1645 (a)(1) and (b).
( b ) *Uses and restrictions.* Aluminum powder may be safely used in coloring externally applied cosmetics, including cosmetics intended for use in the area of the eye, in amounts consistent with good manufacturing practice.
( c ) *Labeling.* The color additive and any mixture prepared therefrom intended solely or in part for coloring purposes shall bear, in addition to any information required by law, labeling in accordance with the provisions of § 70.25 of this chapter.
( d ) *Exemption from certification.* Certification of this color additive is not necessary for the protection of the public health, and therefore batches thereof are exempt from the certification pursuant to section 721(c) of the act.
[42 FR 38563, July 29, 1977]
# C_2015127EN.01002801.xml

| 20.4.2015 | EN | Official Journal of the European Union | C 127/28 |
| --- | --- | --- | --- |

20.4.2015

EN

Official Journal of the European Union

C 127/28

---

Order of the President of the General Court of 27 February 2015 — Spain v Commission

(Case T-826/14 R)

((Interim measures - State aid - Regime of taxation on companies enabling undertakings that are tax resident in Spain to amortise the financial goodwill resulting from the acquisition of shareholdings in companies that are tax resident abroad - Decision declaring the aid incompatible with the internal market and ordering its recovery - Application for a stay of execution - Prima facie Case - Lack of urgency))

(2015/C 127/38)

Language of the case: Spanish

Parties

Parties

Applicant: Kingdom of Spain (represented by: M. Sampol Pucurull, acting as Agent)

Applicant:

Defendant: European Commission (represented by: B. Stromsky, C. Urraca Caviedes and P. Němečková, acting as Agents)

Defendant:

Re:

Re:

Application for a stay of execution of Commission Decision C (2014) 7280 final of 15 October 2014 on State aid SA.35550 (2013/C) (ex 2013/NN) implemented by Spain and concerning the regime for the tax amortisation of financial goodwill for foreign shareholding acquisitions.

Operative part of the order

Operative part of the order

| 1. | The application for interim measures is dismissed. |
| --- | --- |

1.

The application for interim measures is dismissed.

| 2. | The order of 8 January 2015 delivered in Case T-826/14 R is cancelled. |
| --- | --- |

2.

The order of 8 January 2015 delivered in Case T-826/14 R is cancelled.

| 3. | The costs are reserved. |
| --- | --- |

3.

The costs are reserved.

---
Editorial Note on Part 880
Editorial Note: Nomenclature changes to part 880 appear at 73 FR 35341, June 23, 2008.

§ 880.5220 Intravenous catheter force-activated separation device. ( a ) *Identification.* An intravenous catheter force-activated separation device is placed in-line with an intravenous (IV) catheter and an intravascular administration set, including any administration set accessories. It separates into two parts when a specified force is applied. The device is intended to reduce the risk of IV catheter failure(s) requiring IV catheter replacement.
( b ) *Classification.* Class II (special controls). The special controls for this device are: ( 1 ) Performance data must be provided to demonstrate clinically acceptable performance for the intended use of the device.
( 2 ) Non-clinical performance testing must demonstrate that the device performs as intended under anticipated conditions of use. The following performance characteristics must be tested: ( i ) Separation force testing;
( ii ) Validation of anti-reconnect features;
( iii ) Air and liquid leakage testing, both before and after separation;
( iv ) Luer connection testing;
( v ) Flow rate testing;
( vi ) Particulate testing; and
( vii ) Microbial ingress testing.
( 3 ) The device must be demonstrated to be biocompatible.
( 4 ) Performance testing must demonstrate that the device is sterile and non-pyrogenic.
( 5 ) Performance testing must support the shelf life of the device by demonstrating continued sterility and device functionality over the identified shelf life.
( 6 ) Device labeling must include: ( i ) Instructions for use; and
( ii ) A discussion of catheter dressings intended to be used with the device.
[89 FR 66560, Aug. 16, 2024]
Editorial Note on Part 870
Editorial Note: Nomenclature changes to part 870 appear at 73 FR 35341, June 23, 2008.

§ 870.3545 Ventricular bypass (assist) device. ( a ) *Identification.* A ventricular bypass (assist) device is a device that assists the left or right ventricle in maintaining circulatory blood flow. The device is either totally or partially implanted in the body.
( b ) *Classification.* Class III (premarket approval).
( c ) *Date PMA or notice of completion of PDP is required.* A PMA or notice of completion of a PDP is required to be filed with the Food and Drug Administration on or before November 21, 2011, for any ventricular bypass (assist) device that was in commercial distribution before May 28, 1976, or that has, on or before November 21, 2011, been found to be substantially equivalent to any ventricular bypass (assist) device that was in commercial distribution before May 28, 1976. Any other ventricular bypass (assist) device shall have an approved PMA or declared completed PDP in effect before being placed in commercial distribution.
[45 FR 7907, Feb. 5, 1980, as amended at 52 FR 17736, May 11, 1987; 76 FR 50666, Aug. 16, 2011]
Editorial Note on Part 870
Editorial Note: Nomenclature changes to part 870 appear at 73 FR 35341, June 23, 2008.

§ 870.1300 Catheter cannula. ( a ) *Identification.* A catheter cannula is a hollow tube which is inserted into a vessel or cavity; this device provides a rigid or semirigid structure which can be connected to a tube or connector.
( b ) *Classification.* Class II (performance standards).
Editorial Note on Part 880
Editorial Note: Nomenclature changes to part 880 appear at 73 FR 35341, June 23, 2008.

§ 880.6350 Battery-powered medical examination light. ( a ) *Identification.* A battery-powered medical examination light is a battery-powered device intended for medical purposes that is used to illuminate body surfaces and cavities during a medical examination.
( b ) *Classification.* Class I (general controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter, subject to the limitations in § 880.9. The device also is exempt from the current good manufacturing practice requirements of the quality system regulation in part 820 of this chapter, with the exception of § 820.180, with respect to general requirements concerning records, and § 820.198, with respect to complaint files.
[45 FR 69682, Oct. 21, 1980, as amended at 66 FR 38806, July 25, 2001]
§ 884.1630 Colposcope. ( a ) *Identification.* A colposcope is a device designed to permit direct viewing of the tissues of the vagina and cervix by a telescopic system located outside the vagina. It is used to diagnose abnormalities and select areas for biopsy. This generic type of device may include a light source, cables, and component parts.
( b ) *Classification.* Class II (special controls). The device, when it is a standard colposcope (or colpomicroscope) that uses only a white light source, does not use filters other than a green filter, does not include image analysis software, and is not smartphone-based, is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 884.9.
[45 FR 12684, Feb. 26, 1980, as amended at 84 FR 71816, Dec. 30, 2019]
§ 884.5980 Surgical mesh for transvaginal pelvic organ prolapse repair. ( a ) *Identification.* Surgical mesh for transvaginal pelvic organ prolapse repair is a prescription device intended to reinforce soft tissue in the pelvic floor. This device is a porous implant that is made of synthetic material, non-synthetic material, or a combination of synthetic and non-synthetic materials. This device does not include surgical mesh for other intended uses (§ 878.3300 of this chapter).
( b ) *Classification.* Class III (premarket approval).
( c ) *Date premarket application approval or notice of completion of a product development protocol is required.* A premarket application approval or notice of completion of a product development protocol for a device is required to be filed with the Food and Drug Administration on or before July 5, 2018, for any surgical mesh described in paragraph (a) of this section that was in commercial distribution before May 28, 1976, or that has, on or before July 5, 2018, been found substantially equivalent to a surgical mesh described in paragraph (a) of this section that was in commercial distribution before May 28, 1976. Any other surgical mesh for transvaginal pelvic organ prolapse repair shall have an approved premarket application or declared completed product development protocol in effect before being placed in commercial distribution.
[81 FR 361, Jan. 5, 2016, as amended at 81 FR 369, Jan. 5, 2016]
<PAGE>
                                                                    EXHIBIT 4.17


                              CERTIFICATE OF TRUST
                                       OF
                              AGCO CAPITAL TRUST I


         THIS CERTIFICATE OF TRUST of AGCO Capital Trust I (the "Trust") is
being duly executed and filed by the undersigned, as trustee of the Trust, to
form a statutory trust under the Delaware Statutory Trust Act (12 Del. C.
ss. 3801, et seq.) (the "Act").

         1.   Name.  The name of the statutory trust being formed hereby is AGCO
Capital Trust I.

         2.   Delaware Trustee.  The name and business address of the trustee of
the Trust, with a principal place of business in the State of Delaware, is
SunTrust Delaware Trust Company, 1011 Centre Road, Suite 205, Wilmington,
Delaware 19805.

         3.   Effective Date.  This Certificate of Trust shall be effective as
of its filing.

         IN WITNESS WHEREOF, the undersigned has executed this Certificate of
Trust in accordance with Section 3811(a)(1) of the Act.



                         SUNTRUST DELAWARE TRUST COMPANY,
                           as Trustee


                         By: /s/ Jack Ellerin
                         Name: Jack Ellerin
                         Title: Trust Officer